Patients

VENT-03 Clinical Trials

Phase 2 lupus trial: Now Enrolling

Our Phase 2 clinical study evaluating VENT-03 is enrolling adults with lupus who have active cutaneous manifestations between the ages of 18 and 70 years old.

Learn more here.

Phase 1 trial in healthy volunteers: Completed

The successfully completed Phase 1 trial in healthy volunteers demonstrated that VENT-03 is safe and well-tolerated. VENT-03’s robust target engagement and favorable pharmacokinetic profile enables once-daily dosing.

Learn more about the Phase 1 trial here.

VENT-02 Clinical Trials

Phase 2 Parkinson’s disease trial: dosing completed

Our Phase 2 clinical trial of VENT-02 enrolled patients with mild to moderate Parkinson’s disease, between the ages of 45 and 90 years old.

Phase 1 trial in healthy volunteers: Completed

In the successfully completed Phase 1 trial, VENT-02 was well-tolerated at clinical doses, with no dose-limiting safety findings or serious adverse events reported. VENT-02 demonstrated full target engagement and potential for once-daily dosing.

Learn more about the Phase 1 trial here.

Expanded Access Statement

Expanded access (compassionate use) is the use of an investigational medicine for patients with serious or life-threatening conditions prior to approval or outside clinical trials. Ventus does not currently have an expanded access program. Please visit clinicaltrials.gov to determine if you qualify for a clinical trial and discuss options and risks with your healthcare provider.